Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

A new method improves betulin delivery in experiments, showing promise against certain tumors.

Bimekizumab effectively treated a man's chronic beard hair loss.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

Short-acting testosterone injections in a clinic are a preferred treatment for low testosterone because they work well, are convenient, and patients stick with the treatment.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

Ritlecitinib works well and is safe for treating alopecia areata.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Statins may help treat alopecia areata by reducing harmful immune interactions.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

An 87-year-old man showed unusual signs of Hodgkin lymphoma, primarily high calcium levels, which improved after treatment and revealed the disease.

Metatrials could improve clinical research in nephrology by speeding up data collection and overcoming challenges like patient recruitment.

JAK inhibitors show promise for treating various skin diseases.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A mutation in the IKZF1 gene causes immune system overactivity, linked to autoimmune diseases like lupus.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

PCR genotyping in cre-loxP mice can be inaccurate due to unintended gene deletions in non-target tissues.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Interferon alfa-2a is effective for treating cutaneous T cell lymphoma but has significant side effects.